An Open-Label, Randomized, Parallel-Group Study of Bendamustine Hydrochloride and Rituximab(BR)Compared With Rituximab, Cyclophosphamide, Vincristine, and Prednisone (R-CVP) or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednison (R-CHOP) in the First-Line Treatment of Patients With Advanced Indolent Non-Hodgkins Lymphoma (NHL)or Mantle Cell Lymphoma (MCL)

UVA Health System, Department of Medicine, Division of Hematology Oncology seeks volunteers for a research study, who are adults 18 and older with advanced indolent non-Hodgkins lymphoma or mantle cell lymphoma who have never received treatment for lymphoma.

The purpose of the study is to compare the safety and effectiveness of the combination of experimental chemotherapy with bendamustine and rituximab to standard chemotherapy (R-CHOP or R-CVP). Treatment during the study lasts five to eight months, with a follow up period of at least five years. Study involves taking experimental or standard chemotherapy, blood draws, biopsies, and scans and surveys of overall well-being.

Compensation

• Bendamustine provided free of charge
  
• Participant's insurance company will be billed for other medications, tests and procedures considered part of the standard care for patients.
  
• Certain visits and tests required only for the research study that are not covered by insurance will not be charged to participants
  
• Participant's travel and other out-of-pocket expenses may be covered by the study sponsor.
  
• No other compensation is provided for this study.